These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8260118)

  • 1. Continuous versus intermittent sulphonylurea therapy in non-insulin-dependent diabetes mellitus.
    Grunberger G
    Drug Saf; 1993 Oct; 9(4):249-53. PubMed ID: 8260118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
    Langtry HD; Balfour JA
    Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharma-clinics. Medication of the month. Glimepiride (Amarylle)].
    Scheen AJ
    Rev Med Liege; 2000 Mar; 55(3):184-6. PubMed ID: 10823010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a concentration-effect relationship for sulphonylureas?
    Melander A; Donnelly R; Rydberg T
    Clin Pharmacokinet; 1998 Mar; 34(3):181-8. PubMed ID: 9533980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of sulphonylureas in the management of type 2 diabetes mellitus.
    Rendell M
    Drugs; 2004; 64(12):1339-58. PubMed ID: 15200348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team.
    Landstedt-Hallin L; Arner P; Lins PE; Bolinder J; Olsen H; Groop L
    Diabet Med; 1999 Oct; 16(10):827-34. PubMed ID: 10547209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
    Olsson PO; Lindström T
    Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of sulphonylureas in the elderly.
    Graal MB; Wolffenbuttel BH
    Drugs Aging; 1999 Dec; 15(6):471-81. PubMed ID: 10641958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.
    Marchetti P; Navalesi R
    Clin Pharmacokinet; 1989 Feb; 16(2):100-28. PubMed ID: 2656043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
    Inzucchi SE; Tunceli K; Qiu Y; Rajpathak S; Brodovicz KG; Engel SS; Mavros P; Radican L; Brudi P; Li Z; Fan CP; Hanna B; Tang J; Blonde L
    Diabetes Obes Metab; 2015 Oct; 17(10):956-64. PubMed ID: 25962401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic optimisation of oral hypoglycaemic therapy.
    Marchetti P; Giannarelli R; di Carlo A; Navalesi R
    Clin Pharmacokinet; 1991 Oct; 21(4):308-17. PubMed ID: 1760902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
    Burant CF; Viswanathan P; Marcinak J; Cao C; Vakilynejad M; Xie B; Leifke E
    Lancet; 2012 Apr; 379(9824):1403-11. PubMed ID: 22374408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.
    Melander A; Bitzén PO; Faber O; Groop L
    Drugs; 1989 Jan; 37(1):58-72. PubMed ID: 2651086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
    Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
    Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.